<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03258541</url>
  </required_header>
  <id_info>
    <org_study_id>TraceIT_01268</org_study_id>
    <nct_id>NCT03258541</nct_id>
  </id_info>
  <brief_title>Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy</brief_title>
  <official_title>TraceIT® Hydrogel Spacer Injections for Vagina and Erectile Bundles Sparing in Rectal Cancer Patients Treated With Neoadjuvant Radiotherapy: a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Zilli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      For advanced rectal tumors, the standard of care is neoadjuvant radiotherapy (RT) +/-&#xD;
      chemotherapy followed by surgery 8-10 weeks later. Despite its proven efficacy in reducing&#xD;
      local relapse, the neo-adjuvant treatment has been associated to non-negligible side effects,&#xD;
      especially in terms of impaired sexual function. For females, pelvic RT is frequently&#xD;
      associated to long-term complications such as vaginal stenosis (VS), vaginal dryness, and&#xD;
      dyspareunia, while in men RT doses delivered to the neurovascular peri-prostatic bundles and&#xD;
      penile bulb have been associated to the risk to develop erectile dysfunction.&#xD;
&#xD;
      In prostate cancer, hydrogel spacers have been evaluated to create space between the target&#xD;
      (prostate) and the organ (rectum) to be spared during radiotherapy treatments. Clinical&#xD;
      studies have shown the ease of spacer application; patient tolerance and, good clinical&#xD;
      outcomes (decrease in rectal toxicities).&#xD;
&#xD;
      This pilot study wishes to investigate feasibility and efficacy of the injected hydrogel&#xD;
      spacers TraceIT® in sparing vagina/prostate in the treatment of rectal cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a feasibility prospective pilot study. Ten patients (5 males and 5 females) with a&#xD;
      histologically proven locally advanced rectal cancer with the indication of neoadjuvant&#xD;
      radiotherapy or radio-chemotherapy will be recruited for this study. Prior to enrollment,&#xD;
      potential candidates will undergo a thorough physical and clinical examination and&#xD;
      documentation on medical and surgical history. If eligible, a baseline planning computed&#xD;
      tomography (CT) simulation will be performed at the Radiation Oncology Department before the&#xD;
      TraceIT® implant. Participants will undergo a transperineal injection of TraceIT® spacer gel&#xD;
      between rectum and vagina or prostate performed by a trained radiologist under transrectal&#xD;
      ultrasound guidance. A CT simulation will be repeated within 3 to 5 days post injection using&#xD;
      the same imaging modality and treatment position used the pre- TraceIT® injection. Radiation&#xD;
      treatment plans will be generated using scans realized pre- and post- TraceIT® injection and&#xD;
      compared using dose volume histograms (DVH) analyses. Tolerance, side effects, and adverse&#xD;
      events related to the procedure will be recorded prospectively from the injection until&#xD;
      week-4 after EBRT (External Beam Radiation Therapy) completion. Radiological status of the&#xD;
      spacer will be evaluated on the preoperative magnetic resonance Imaging (MRI).&#xD;
      Histopathological results and any serious and/or unanticipated adverse events following&#xD;
      surgery procedure will be recorded retrospectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Surgical access not facilitated- residues of hydrogel.&#xD;
  </why_stopped>
  <start_date type="Actual">January 15, 2017</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical performance</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of serious adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative dosimetric studies</measure>
    <time_frame>2 years</time_frame>
    <description>Dosimetric parameters to determine effectiveness of this technique to reduce RT (radiotherapy) doses to the vagina/erectile bundles as assessed by comparative dosimetric studies.</description>
  </secondary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Rectal Tumors</condition>
  <condition>Rectal Cancer</condition>
  <condition>Advanced Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TraceIT®</intervention_name>
    <description>This pilot study wishes to investigate feasibility and efficacy of the injected hydrogel spacers TraceIT® in sparing vagina/prostate in the treatment of rectal cancer patients.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Volumetric Arc Therapy (VMAT)</intervention_name>
    <description>VMAT - fractionation Schedule : 1.8 Gy per fraction, one fraction per day, 5 fractions per week for the elective PTV and 2 Gy per fraction, one fraction per day, 5 fractions per week for the PTV-boost using a simultaneous integrated boost technique.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Low anterior resection of the rectum: 8-10 weeks post-radiotherapy</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  WHO (World Health Organization) performance status 0-1 at registration&#xD;
&#xD;
          -  Locally advanced (T1-2 node positive or T3 N0/N+) histologically proven rectal&#xD;
             adenocarcinoma located in the middle or in the high rectum. Patients with tumors&#xD;
             located in the lower rectum may be eligible if the location of the tumor do not&#xD;
             preclude the implant of the spacer (i.e. tumors located anteriorly in the proximity of&#xD;
             the anal sphincter)&#xD;
&#xD;
          -  Indication for preoperative radiotherapy or radio-chemotherapy&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological, or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  Before patient registration/randomization, written informed consent must be given&#xD;
             according to GCP/ICH (Guideline for Good Clinical Practice/Harmonised Tripartite&#xD;
             Guideline), and national/local regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient &lt;18 years old&#xD;
&#xD;
          -  WHO performance status ≥ 2 at registration&#xD;
&#xD;
          -  Patient with a local extension, clinical stage T4 and/or presenting a&#xD;
             vagina/prostate/bladder invasion&#xD;
&#xD;
          -  Active bleeding disorder or clinically significant coagulopathy (PTT &gt;35sec/ or INR&#xD;
             &gt;1.4 (INR, international normalized ratio). Or platelet count &lt; 100'000/mm3)&#xD;
&#xD;
          -  Active inflammatory or infectious process involving the perineum, gastrointestinal or&#xD;
             urinary tract&#xD;
&#xD;
          -  Compromised immune system (e.g. HIV/acquired immunodeficiency syndrome, autoimmune&#xD;
             disease or immunosuppressive therapy)&#xD;
&#xD;
          -  History of previous pelvic surgery&#xD;
&#xD;
          -  History of active inflammatory bowel disease (Crohn's disease, ulcerative colitis,&#xD;
             irritable bowel disease)&#xD;
&#xD;
          -  Contraindication for MRI&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Inability to provide a written informed consent&#xD;
&#xD;
          -  Inability to comply with study and follow up procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Geneva</name>
      <address>
        <city>Genève</city>
        <zip>1205</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 17, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2017</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Thomas Zilli</investigator_full_name>
    <investigator_title>MD, PD, Médecin adjoint agrégé</investigator_title>
  </responsible_party>
  <keyword>TraceIT®</keyword>
  <keyword>Hydrogel spacer</keyword>
  <keyword>Rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

